ENVB - Enveric Biosciences, Inc.
1.98
-0.110 -5.556%
Share volume: 92,329
Last Updated: 03-05-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.31%
PREVIOUS CLOSE
CHG
CHG%
$2.09
0.00
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-15-2024 | 08-12-2024 | 11-14-2024 | 03-28-2025 | 05-14-2025 | 08-14-2025 | 11-14-2025 | |
| Assets | ||||||||
| Total Assets | 8.850 M | 6.052 M | 4.790 M | 3.083 M | 5.102 M | 3.548 M | 4.362 M | |
| Current Assets | 8.229 M | 5.520 M | 4.338 M | 2.735 M | 4.835 M | 3.307 M | 4.166 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 6.356 M | 3.503 M | 3.112 M | 2.241 M | 4.294 M | 2.850 M | 3.758 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 452.228 K | 405.114 K | 367.689 K | 305.777 K | 267.279 K | 241.082 K | 196.521 K | |
| Other Assets | 168.744 K | 126.556 K | 84.368 K | 42.182 K | 0.000 | 0.000 | 0.000 | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 8.850 M | 6.052 M | 4.790 M | 3.083 M | 5.102 M | 3.548 M | 4.362 M | |
| Total liabilities | 2.368 M | 645.340 K | 839.166 K | 1.490 M | 1.184 M | 1.364 M | 905.885 K | |
| Total current liabilities | 2.368 M | 645.340 K | 839.166 K | 1.490 M | 1.184 M | 1.364 M | 905.885 K | |
| Accounts Payable | 1.853 M | 459.898 K | 576.324 K | 521.747 K | 1.083 M | 1.264 M | 905.885 K | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 6.482 M | 5.406 M | 3.951 M | 1.593 M | 3.918 M | 2.185 M | 3.456 M | |
| Common stock | 105.990 M | 106.809 M | 107.406 M | 108.262 M | 112.775 M | 113.537 M | 116.689 M | |
| Retained earnings | -98.956 M | -100.836 M | -102.920 M | -106.075 M | -108.259 M | -110.779 M | -112.652 M |